Drug-Induced Liver Injury in Patients With Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage?

Gastroenterology

Volumn 151, Issue 6, 2016, Pages 1046-1051

  Chalasani, Naga ^a   Regev, Arie ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DRUG; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; ALGORITHM; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE; DECOMPENSATED LIVER CIRRHOSIS; DRUG MONITORING; EDITORIAL; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; NONALCOHOLIC FATTY LIVER; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; SCREENING; TOXIC HEPATITIS; CHRONIC DISEASE; LIVER DISEASE; MORTALITY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

CHEMICAL AND DRUG INDUCED LIVER INJURY; CHRONIC DISEASE; HUMANS; LIVER DISEASES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84997207111     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.10.010     Document Type: Editorial

References (26)

1. 1 Food and Drug Administration. Drug-induced livery injury: premarketing clinical evaluation. In: Guidance for industry. 2009. Available: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf. Accessed August 1, 2016.
2. 2 Health Canada. Guidance document: pre-market evaluation of hepatotoxicity in health products. 2012. Available: www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/hepatotox_guide_ld-eng.php. Accessed August 1, 2016.
3. 3 Watkins, P.B., Seligman, P.J., Pears, J.S., et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 48 (2008), 1680–1689.
4. 4 Aithal, G.P., Watkins, P.B., Andrade, R.J., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 89 (2011), 806–815.
5. 5 Regev, A., Seeff, L.B., Merz, M., et al. Causality assessment for suspected DILI during clinical phases of drug development. Drug Safety 37:Suppl 1 (2014), S47–S56.
6. 6 Avigan, M.I., Bjornsson, E.S., Pasanen, M., et al. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. Drug Safety 37:Suppl 1 (2014), S19–S31.
7. 7 Wong, W.M., Wu, P.C., Yuen, M.F., et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31 (2000), 201–206.
8. 8 Chalasani, N., Aljadhey, H., Kesterson, J., et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 126 (2004), 1287–1292.
9. 9 Chalasani, N., Bjornsson, E., Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 138 (2010), 2246–2259.
10. 10 Lewis, J.H., The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf 1 (2002), 159–172.
11. 11 Russo, M.W., Watkins, P.B., Are patients with elevated liver tests at increased risk of drug-induced liver injury?. Gastroenterology 126 (2004), 1477–1480.
12. 12 Chalasani, N., Bonkovsky, H.L., Fontana, R., et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 148 (2015), 1340–1352.
13. 13 Moylan, C.A., Suzuki, A., Papay, J.I., et al. A pre-marketing ALT signal predicts post-marketing liver safety. Regul Toxicol Pharm 63 (2012), 433–439.
14. 14 Sanyal, A.J., Brunt, E.M., Kleiner, D.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54 (2011), 344–353.
15. 15 Regev, A., Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis 34 (2014), 227–239.
16. 16 Zimmerman, H.J., Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver, 2nd ed., 1999, Lippincott, Williams& Wilkins, Philadelphia, 428–430.
17. 17 Temple, R., Hy's law: predicting serious hepatotoxicity. Pharmacoepidem Dr S 15 (2006), 241–243.
18. 18 Bjornsson, E., Olsson, R., Outcome and prognostic markers in severe drug induced liver disease. Hepatology 42 (2005), 481–489.
19. 19 Andrade, R.J., Lucena, M.I., Fernandez, M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005), 512–521.
20. 20 Fontana, R.J., Hayashi, P.H., Gu, J., et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 147 (2014), 96–108.
21. 21 Parks, D., Lin, X., Painter, J.L., et al. A proposed modification to Hy's law and eDISH criteria in oncology clinical trials using aggregated historical data. Pharmacoepidem Drug Saf 22 (2013), 571–578.
22. 22 Im, G.Y., Kazi, S., Thung, S.N., et al. A maxed-out liver: a case of acute-on-chronic liver failure. Semin Liver Dis 3 (2011), 420–426.
23. 23 Jalan, R., Gines, P., Olson, J.C., et al. Acute-on chronic liver failure. J Hepatol 57 (2012), 1336–1348.
24. 24 Arroyo, V., Moreau, R., Kamath, P.S., et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers 2 (2016), 1–18.
25. 25 Food and Drug Administration. Safety assessment for IND safety reporting. Guidance for industry. Available: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm477584.pdf Accessed August 1, 2016.
26. 26 Bjornsson, E.S., Hoofnagle, J.H., Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology 63 (2016), 590–603.